Myriad Genetics downgraded by Leerink Partners with a new price target

12/9/24 8:00:35 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Leerink Partners downgraded Myriad Genetics from Outperform to Market Perform and set a new price target of $21.00 from $30.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MYGN

Date	Price Target	Rating	Analyst
5/21/2025	$6.00	Sector Outperform → Sector Perform	Scotiabank
5/8/2025		Outperform → Peer Perform	Wolfe Research
5/7/2025	$6.00	Overweight → Equal Weight	Wells Fargo
4/9/2025		Buy → Neutral	Guggenheim
3/12/2025	$11.50 → $12.50	Neutral → Overweight	Piper Sandler
2/12/2025	$29.00	Buy	Craig Hallum
12/10/2024	$18.00	Neutral	UBS
12/9/2024	$30.00 → $21.00	Outperform → Market Perform	Leerink Partners